Change from baseline in PWV (LOCF), ITT population
| Placebo+MTX (n=63) | TCZ 8 mg/kg+MTX (n=69) | 95% CI (p) for difference | |
|---|---|---|---|
| Baseline | |||
| n | 59 | 69 | |
| Mean (SD) PWV, m/s | 9.0 (2.5) | 9.0 (2.0) | |
| Week 12 | |||
| n | 62 | 69 | |
| Mean (SD) PWV, m/s | 8.4 (1.8) | 8.9 (2.5) | |
| Mean change from baseline in PWV, m/s | –0.99 | –0.21 | 0.22 to 1.35 (p=0.0067) |
| Week 24 | |||
| n | 62 | 69 | |
| Mean (SD) PWV, m/s | 8.9 (2.0) | 9.0 (2.3) | |
| Mean change from baseline in PWV, m/s | –0.47 | –0.17 | –0.27 to 0.87 (p=0.3042) |
LOCF was used for missing values. Only postbaseline and pre-escape therapy scores were carried forward. All assessments were set to missing from the time of escape therapy. Mean change from baseline was adjusted for baseline age, C-reactive protein level and mean arterial pressure.
ITT, intent-to-treat; LOCF, last-observation-carried-forward; MTX, methotrexate; PWV, pulse wave velocity; TCZ, tocilizumab.